Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 65Neoplasms 31Small Cell Lung Carcinoma 26Carcinoma, Hepatocellular 24Melanoma 23Colorectal Neoplasms 23Triple Negative Breast Neoplasms 20Carcinoma, Renal Cell 20Carcinoma, Transitional Cell 19Breast Neoplasms 18Neoplasm Metastasis 14Urinary Bladder Neoplasms 13Stomach Neoplasms 12Uterine Cervical Neoplasms 11Solid Tumors 11Squamous Cell Carcinoma of Head and Neck 10Ovarian Neoplasms 8Lymphoma 7Lung Neoplasms 7Lymphoma, Non-Hodgkin 6Head and Neck Neoplasms 6Esophageal Neoplasms 6Pancreatic Neoplasms 5Liver Neoplasms 5Carcinoma, Merkel Cell 5Advanced Solid Tumor 5Solid Tumor 4Prostatic Neoplasms 4Leukemia, Myeloid, Acute 4Kidney Neoplasms 4

Interventions

atezolizumab 1Pemetrexed 1Gemcitabine 1Cisplatin 1Carboplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-Small-Cell Lung × atezolizumab × Clear all
NCT03456063 2026-01-22

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Hoffmann-La Roche

Phase 3 Completed
453 enrolled
Thoracic

Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡